Medicure completes Phase I MC-1 trial
Medicure has successfully completed a Phase I clinical trial of its MC-1treatment for heart attack patients that has demonstrated the drug's safety profile at expected therapeutic doses. The company will apply to the US Food and Drug Administration and to Canada's Therapeutic Products Directorate for approval to start a Phase II trial which will evaluate the drug's ability to reduce heart damage from myocardial infarction and protect the heart against injury as a result of coronary bypass surgery and angioplasty.
Meantime, Medicure has announed that it has granted 20,000 stock options at a price of $1.25 per common share to certain directors, officers and employees.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze